Cargando…

A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan

BACKGROUND: Comorbidities and stages may influence the prognosis of melanoma patients in Taiwan and need to be determined. METHODS: We performed a retrospective cohort study by using the national health insurance research database in Taiwan. Patients with a primary diagnosis of melanoma by the Taiwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chin-Kuo, Hsieh, Yih-Shou, Chen, Pei-Ni, Chu, Shu-Chen, Huang, Jing-Yang, Wang, Yu-Hsun, Wei, James Cheng-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927660/
https://www.ncbi.nlm.nih.gov/pubmed/35311079
http://dx.doi.org/10.3389/fonc.2022.846760
_version_ 1784670490495811584
author Chang, Chin-Kuo
Hsieh, Yih-Shou
Chen, Pei-Ni
Chu, Shu-Chen
Huang, Jing-Yang
Wang, Yu-Hsun
Wei, James Cheng-Chung
author_facet Chang, Chin-Kuo
Hsieh, Yih-Shou
Chen, Pei-Ni
Chu, Shu-Chen
Huang, Jing-Yang
Wang, Yu-Hsun
Wei, James Cheng-Chung
author_sort Chang, Chin-Kuo
collection PubMed
description BACKGROUND: Comorbidities and stages may influence the prognosis of melanoma patients in Taiwan and need to be determined. METHODS: We performed a retrospective cohort study by using the national health insurance research database in Taiwan. Patients with a primary diagnosis of melanoma by the Taiwan Cancer Registry from 2009 to 2017 were recruited as the study population. The comparison group was never diagnosed with melanoma from 2000 to 2018. The Charlson comorbidity index was conducted to calculate the subjects’ disease severity. The Cox proportional hazards model analysis was used to estimate the hazard ratio of death. RESULTS: We selected 476 patients, 55.5% of whom had comorbidity. A higher prevalence of comorbidity was associated with a more advanced cancer stage. The mortality rate increased with an increasing level of comorbidity in both cohorts and was higher among melanoma patients. The interaction between melanoma and comorbidity resulted in an increased mortality rate. CONCLUSION: An association between poorer survival and comorbidity was verified in this study. We found that the level of comorbidity was strongly associated with mortality. A higher risk of mortality was found in patients who had localized tumors, regional metastases, or distant metastases with more comorbidity scores. Advanced stage of melanoma patients with more comorbidities was significantly associated with the higher risk of mortality rate.
format Online
Article
Text
id pubmed-8927660
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89276602022-03-18 A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan Chang, Chin-Kuo Hsieh, Yih-Shou Chen, Pei-Ni Chu, Shu-Chen Huang, Jing-Yang Wang, Yu-Hsun Wei, James Cheng-Chung Front Oncol Oncology BACKGROUND: Comorbidities and stages may influence the prognosis of melanoma patients in Taiwan and need to be determined. METHODS: We performed a retrospective cohort study by using the national health insurance research database in Taiwan. Patients with a primary diagnosis of melanoma by the Taiwan Cancer Registry from 2009 to 2017 were recruited as the study population. The comparison group was never diagnosed with melanoma from 2000 to 2018. The Charlson comorbidity index was conducted to calculate the subjects’ disease severity. The Cox proportional hazards model analysis was used to estimate the hazard ratio of death. RESULTS: We selected 476 patients, 55.5% of whom had comorbidity. A higher prevalence of comorbidity was associated with a more advanced cancer stage. The mortality rate increased with an increasing level of comorbidity in both cohorts and was higher among melanoma patients. The interaction between melanoma and comorbidity resulted in an increased mortality rate. CONCLUSION: An association between poorer survival and comorbidity was verified in this study. We found that the level of comorbidity was strongly associated with mortality. A higher risk of mortality was found in patients who had localized tumors, regional metastases, or distant metastases with more comorbidity scores. Advanced stage of melanoma patients with more comorbidities was significantly associated with the higher risk of mortality rate. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8927660/ /pubmed/35311079 http://dx.doi.org/10.3389/fonc.2022.846760 Text en Copyright © 2022 Chang, Hsieh, Chen, Chu, Huang, Wang and Wei https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chang, Chin-Kuo
Hsieh, Yih-Shou
Chen, Pei-Ni
Chu, Shu-Chen
Huang, Jing-Yang
Wang, Yu-Hsun
Wei, James Cheng-Chung
A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan
title A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan
title_full A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan
title_fullStr A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan
title_full_unstemmed A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan
title_short A Cohort Study: Comorbidity and Stage Affected the Prognosis of Melanoma Patients in Taiwan
title_sort cohort study: comorbidity and stage affected the prognosis of melanoma patients in taiwan
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927660/
https://www.ncbi.nlm.nih.gov/pubmed/35311079
http://dx.doi.org/10.3389/fonc.2022.846760
work_keys_str_mv AT changchinkuo acohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT hsiehyihshou acohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT chenpeini acohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT chushuchen acohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT huangjingyang acohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT wangyuhsun acohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT weijameschengchung acohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT changchinkuo cohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT hsiehyihshou cohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT chenpeini cohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT chushuchen cohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT huangjingyang cohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT wangyuhsun cohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan
AT weijameschengchung cohortstudycomorbidityandstageaffectedtheprognosisofmelanomapatientsintaiwan